Archive: Company News

Company News: Curetis and OpGen Enter Into Definitive Agreement to Combine Businesses


— Combined company creates a commercial-stage, transatlantic diagnostics company focusing on data-driven solutions for molecular microbiology

— Combined company to be headquartered in Gaithersburg, MD, USA

— Transaction is supported by the boards of OpGen and Curetis

— Transaction subject to approval by both companies’ shareholders and debt financing providers

— Conference call scheduled for September 4, 2019, at 9:00 am Eastern / 3:00 pm Central European Time Read more…

Company News: ISA Pharmaceuticals Strengthens its Supervisory Board with the Addition of Dr. Markwin Velders

– Seasoned biotech expert to support corporate development

ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed immunotherapeutics against cancer and persistent viral infections, today announced the addition of Dr. Markwin Velders to its Supervisory Board. Dr. Velders brings many years of experience in the biotech industry and currently holds a position as VP Operations and Managing Director at Kite Pharma EU, a leading company in the field of immuno-oncology and cell therapy. Read more…

Company News: Richter launched Terrosa®, its biosimilar teriparatide across Europe

Gedeon Richter Plc. (“Richter”) today announced that it has launched its biosimilar teriparatide, Terrosa® in Europe. The product is approved in adults for the same indications as Eli Lilly’s Forsteo®, i.e. used for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture and treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture. Read more…

Company News: Curetis Retains H.C. Wainwright & Co. as Strategic Advisor

— Investment bank supports Curetis in assessment of all strategic and tactical financing options  

— Publication of H1-2019 financials postponed to September 18, 2019

— Key financials show EUR 7.8 million cash as of June 30, 2019 and significantly reduced cash burn in H1-2019

Elements of this announcement contain or may contain inside information within the meaning of Article 7(1) of the Market Abuse Regulation.

Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced that it has retained the U.S. based investment bank, H.C. Wainwright & Co., LLC, as strategic advisor in an  effort to assess all available strategic and tactical options going forward to potentially secure appropriate funding and cash for continued operations for at least the next twelve months. Read more…

1 2 3 116